Lista de obras -

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL.

artículo científico publicado en 2017

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

artículo científico publicado en 2016

Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia

artículo científico publicado en 2017

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).

artículo científico publicado en 2016

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

artículo científico publicado en 2011

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

scientific article published on 13 August 2018

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

artículo científico publicado en 2012

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

artículo científico publicado en 2020

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

scientific article published on 19 December 2018

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

artículo científico publicado en 2018

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

artículo científico publicado en 2017

Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects

artículo científico publicado en 2016

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

artículo científico publicado en 2016

Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia

artículo científico publicado en 2015

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

artículo científico publicado en 2014

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

scientific article published on 04 July 2019

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

artículo científico publicado en 2020

Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective

artículo científico publicado en 2016

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota

artículo científico publicado en 2016

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group

artículo científico publicado en 2015

Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual

artículo científico publicado en 2013

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

artículo científico publicado en 2016

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

artículo científico publicado en 2016

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription

scientific article published on 29 August 2019

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

scientific article published on 01 March 2020

International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia

artículo científico publicado en 2020

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

artículo científico publicado en 2017

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis ⬇️

artículo científico publicado el 7 de diciembre de 2010

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

artículo científico publicado en 2020

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

artículo científico publicado en 2015

Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group

artículo científico publicado en 2015

Machine learning can identify newly diagnosed patients with CLL at high risk of infection

scientific article published on 17 January 2020

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

artículo científico publicado en 2016

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

scientific article published on 08 July 2019

Mutations driving CLL and their evolution in progression and relapse

artículo científico publicado en 2015

NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib

artículo científico publicado en 2017

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

scientific article published on 20 September 2018

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

artículo científico publicado en 2015

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia

artículo científico publicado en 2018

Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

scientific article published on 12 July 2019

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

scientific article published on 23 March 2020

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

artículo científico publicado en 2019

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

artículo científico publicado en 2020

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

artículo científico publicado en 2018

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

artículo científico publicado en 2013

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

scientific article published on 25 March 2019

Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials

artículo científico publicado en 2019

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression

artículo científico publicado en 2015

The Treatment of Chronic Lymphatic Leukemia

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study

artículo científico publicado en 2019

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia

artículo científico publicado en 2017

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

artículo científico publicado en 2019

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

artículo científico publicado en 2017

Lista de obras de

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL.

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group

Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis ⬇️

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group

Machine learning can identify newly diagnosed patients with CLL at high risk of infection

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

Mutations driving CLL and their evolution in progression and relapse

NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia

Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression

The Treatment of Chronic Lymphatic Leukemia

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Venetoclax and obinutuzumab in chronic lymphocytic leukemia